# Bispecific Antibodies for Targeting Alzheimer's Disease in the Brain > This patent describes special antibodies designed to cross into the brain and target amyloid-beta, a protein linked to Alzheimer's disease. - **Patent:** US 12735497 - **Original title:** Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use - **Granted:** 2026 - **Status:** Active - **Times cited:** 0 - **Field:** biotech, pharmaceutical, neuroscience ## What it does This patent describes special antibodies that are 'bispecific,' meaning they are engineered to attach to two different targets at the same time. One target is human A-beta, a protein linked to Alzheimer's disease. The other target is the human transferrin receptor, a protein found on the blood-brain barrier, which is the protective shield around the brain. The patent provides these specific antibodies and methods for using them, likely to help deliver treatment to the brain for conditions like Alzheimer's disease. ## What it does NOT cover - Antibodies that only target one specific protein (monospecific antibodies), rather than two different ones simultaneously. - Bispecific antibodies that target different combinations of proteins, not specifically human A-beta and the human transferrin receptor. - Methods of treating Alzheimer's disease that do not involve using antibodies to cross the blood-brain barrier via the transferrin receptor. - Other types of treatments for neurodegenerative diseases, such as small molecule drugs or gene therapies, that are not antibody-based. - Antibodies that target A-beta but do not use the transferrin receptor to enter the brain. - Antibodies that target the transferrin receptor but do not also target A-beta. ## The clever bit The clever part is designing a single antibody that can both sneak past the brain's defenses using the transferrin receptor and then specifically attack the amyloid-beta proteins associated with Alzheimer's disease. ## Real-world examples 1. Antibody-based therapies for neurodegenerative diseases 2. Drugs designed to cross the blood-brain barrier 3. Next-generation Alzheimer's treatments ## Why it matters Alzheimer's disease affects millions, and a major challenge in treating it is getting medicines past the blood-brain barrier, a natural defense that protects the brain. This type of antibody aims to overcome that barrier, potentially opening new ways to deliver treatments directly to the brain to target amyloid-beta plaques. ## Frequently asked questions ### What does Bispecific Antibodies for Targeting Alzheimer's Disease in the Brain cover? This patent describes special antibodies designed to cross into the brain and target amyloid-beta, a protein linked to Alzheimer's disease. ### When does this patent expire? This patent is expected to expire on September 15, 2046, when the invention enters the public domain. ### What problem does this patent solve? Alzheimer's disease affects millions, and a major challenge in treating it is getting medicines past the blood-brain barrier, a natural defense that protects the brain. This type of antibody aims to overcome that barrier, potentially opening new ways to deliver treatments directly to the brain to target amyloid-beta plaques. ### What does this patent NOT cover? Antibodies that only target one specific protein (monospecific antibodies), rather than two different ones simultaneously. **Full plain-English explainer:** https://patentbrief.org/patent/us/12735497/bispecific-anti-human-a-betahuman-transferrin-receptor-antibodies-and-methods **Original patent:** https://patents.google.com/patent/US12735497 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [Antibodies to Target Tau Protein in Brain Diseases](https://patentbrief.org/patent/us/12735507/antibodies-recognizing-tau) — This patent describes specific antibodies designed to bind to the tau protein, aiming to slow down or stop brain diseases linked to tau, like Alzheimer's. - [How Roche Engineers Antibodies to Target Two Different Diseases Simultaneously](https://patentbrief.org/patent/us/10138293/opdivo-nivolumab) — A method for creating a custom-engineered antibody that can grab onto two different targets at once, designed to help the immune system fight complex diseases. - [Detecting Alzheimer's Risk Early with a Blood Test and Brain Scan](https://patentbrief.org/patent/us/11193946/blood-biomarker-for-discerning-beta-amyloid-accumulation-in-brain) — This patent describes a two-step method to predict early Alzheimer's disease by first checking specific protein levels in a blood sample, and then, if certain markers are low, performing a brain scan to confirm amyloid beta buildup. - [Diagnosing Brain Diseases by Measuring a Protein in Blood or Urine](https://patentbrief.org/patent/us/20220283184/novel-diagnostic-marker-for-creutzfeldt-jakob-disease-and-alzheimers-disease) — This patent describes a method for diagnosing brain diseases like Alzheimer's and Creutzfeldt-Jakob disease by measuring the amount of a specific protein called beta-synuclein in non-spinal fluid samples such as blood or urine. - [Using Antibodies to Target Tissue Factor Without Stopping Blood Clotting](https://patentbrief.org/patent/us/7993644/stelara-ustekinumab) — A patent describing specific antibodies that attach to a protein called tissue factor without interfering with the body's natural blood-clotting process.